Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2002, the company has established itself as a leader in the development and manufacturing of niche generic and branded pharmaceuticals, particularly in the areas of controlled substances and complex formulations. With a focus on innovative drug delivery systems, Elite Pharmaceuticals offers unique products that cater to unmet medical needs, setting them apart in a competitive market. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and a robust pipeline of products in various stages of development. Recognised for its commitment to quality and compliance, Elite Pharmaceuticals continues to strengthen its market position, contributing to the advancement of healthcare solutions both domestically and internationally.
DitchCarbon Score
How does Elite Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Elite Pharmaceuticals, Inc.'s score of 13 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Elite Pharmaceuticals, Inc.'s reported carbon emissions
Elite Pharmaceuticals, Inc., headquartered in the US, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no documented Scope 1, 2, or 3 emissions to report. In the absence of specific emissions data, it is important to note that the company has not outlined any formal reduction targets or commitments to climate initiatives. This lack of publicly available information suggests that Elite Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability and carbon reduction, it will be essential for Elite Pharmaceuticals to establish clear climate commitments and measurable targets to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Elite Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
